The supervisory layer for the clinical laboratory.
Laboratories automated measurement and sample handling. The next layer is cognitive. Eukrion supervises laboratory quality, production and clinical interpretation continuously, and escalates only what genuinely needs a specialist.
Illustrative example. Eukrion is in development and is not yet a CE-marked medical device.
The gap
The machines are automated. The specialist workload is not.
Track systems and analysers solved the physical production problem. They did not remove the continuous cognitive work that keeps a laboratory safe, in control and clinically useful — and that work depends on the scarcest people in the building.
Quality signals never stop arriving
QC, calibration behaviour, reagent lots, EQA findings and deviations all need judgement, not just thresholds.
Production needs constant watching
Turnaround time, backlog, reruns, sample quality and reagent availability, across every analyser and every shift.
Demand is outgrowing expertise
Diagnostic volume and complexity are rising faster than specialist supervisory capacity in every major market.
Between the measurement and the decision sits judgement.
That is the work Eukrion is built to carry.
The platform
One platform, three intelligence domains
Eukrion Lab connects to laboratory data sources and continuously answers three questions: are the results reliable, is production running safely, and what do these results mean for the patient.
Quality
Are the results analytically reliable and the quality system in control?
QC and EQA surveillance, trend and shift detection, lot-change assessment, deviation support and audit evidence.
Operations
Is production running safely and efficiently?
Analyser state, turnaround time, backlog, reruns, sample quality, reagent status, routing and incident detection.
Clinical
What do the patient results mean, and what should happen next?
Result review, pattern recognition, interpretive comments, reflex and add-on suggestions, and escalation.
Expertise that travels
For large networks, Eukrion means experts manage exceptions instead of continuously scanning routine signals, and quality interpretation stays consistent across instruments, shifts and sites. For smaller laboratories, it supports a hub-and-spoke model in which one centralised specialist oversees several sites while the platform monitors each of them continuously.
Eukrion starts as a supervised copilot. Autonomy is added one validated workflow at a time, and human professionals remain accountable throughout.
Eukrion does not remove statutory or accreditation requirements for qualified personnel. It allows scarce expertise to cover more production and more sites.
Technology
The model is not the moat. The laboratory control system around it is.
Seven layers sit between raw laboratory telemetry and anything a specialist acts on. Deterministic logic and independent safety checks can override the reasoning layer, and the model itself is replaceable. Select a layer to read what it does.
What compounds is the closed loop — laboratory state, anomaly, interpretation, human decision, action, outcome — not the individual report.
Regulatory and quality
Regulation is designed in, not retrofitted
Operational and quality-management functionality is kept separate from functions that provide clinically relevant diagnostic information, so each module carries its own intended purpose, risk controls and evidence. Eukrion is built to fit inside accredited laboratory governance rather than disrupt it.
ISO 15189:2022ISO 13485IEC 62304ISO 14971MDR / IVDR per moduleEU AI Act governance
Contact
Where we are today
Eukrion is an early-stage company being established in Finland. We are building the first release, working toward lighthouse laboratory design partners, and raising a pre-seed round.
We would like to hear from laboratories and hospital networks interested in early collaboration, from investors in clinical AI and diagnostics, and from people who have spent their careers inside laboratory medicine and want to build this.
Get in touch
Tell us a little about your interest and we will come back to you. Detailed company and investor materials are shared on request.
